-
-
-
-
-
-
-
BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
-
-
-
-
-
-
-
BridgeBio Pharma Inc. (BBIO) Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) Announces FDA Acceptance of New Drug Application for Acoramidis
-
-
-
-
-
15,416 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

